Status:
WITHDRAWN
Study of the Neural Substrates of Alcohol Craving by High-resolution Electroencephalography
Lead Sponsor:
Rennes University Hospital
Conditions:
Alcoholism
Alcohol Dependence
Eligibility:
MALE
30-60 years
Phase:
NA
Brief Summary
Alcohol is the most consumed psychoactive substance in France and is responsible for 49,000 deaths per year in the country. Addictions, characterized by "the repeated impossibility of controlling a be...
Detailed Description
The objective of the CRAVING-NET project is to better understand brain function in alcohol addiction, and in particular in craving, using high-resolution electroencephalography. Brain activity followi...
Eligibility Criteria
Inclusion
- Patients (N=20):
- Subject with moderate to severe DSM-5 alcohol use disorder hospitalized for withdrawal as part of their routine care.
- Presence of spontaneous and/or in response to environmental stimuli (induced) self-described episodes of craving.
- Males with age ≥ 30 years and ≤ 60 years;
- Normal or corrected-to-normal visual acuity (declarative);
- Right-handed;
- Healthy control volunteers (N=40):
- Men with age ≥ 30 years and ≤ 60 years;
- Normal or corrected-to-normal visual acuity;
- Right-handed;
- Smoker (current user, N=20) or Nonsmoker (never smoked, N=20);
- Alcohol consumption below the low-risk drinking threshold (\<10 standard drinks per week)
Exclusion
- For all subjects:
- Alcohol use in the 24 hours prior to the experiment;
- Consumption of psychoactive substances other than tobacco and alcohol (positive urine test).
- Presence of a contraindication related to the MRI technique
- Being under legal protection, and/or deprived of freedom;
- Not mastering the French language (written and oral);
- Inability to understand the information given on the study and/or to carry out the experimental task.
- For patients:
- Presence of cognitive impairment (MoCA score \< 25)
- Absence of spontaneous or induced craving episodes
- Decompensated cirrhosis: ascites and/or encephalopathy and/or jaundice and/or recent hemorrhage
- For healthy control volunteers:
- Significant medical or surgical history related to the central nervous system;
- Current use (\< 30 days) of drugs affecting the central nervous system belonging to the class of antidepressants, sleeping pills and/or anxiolytics.
Key Trial Info
Start Date :
May 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05275166
Start Date
May 1 2023
End Date
November 1 2025
Last Update
December 4 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.